Head-to-head evidence
brepocitinib vs TLL-018
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2/JAK1 · full Psoriasis pipeline
brepocitinib · Lisraya
Marketed by Roivant Sciences Ltd. and partners
NCT03850483 · Phase 2 · completed
This was a randomized, quadruple-blinded, vehicle-controlled Phase 2 dose-ranging study in 344 adults with plaque psoriasis, using a well-established clinical endpoint (change in PASI at Week 12). However, the primary endpoint was not met: every active-dose comparison against vehicle was non-significant (p-values from 0.105 to 0.610), with LS mean differences of only -0.2 to -0.8 points. Because the trial was methodologically strong but its primary comparison was negative, the evidence is moderate rather than strong.
TLL-018
Developed by Hangzhou Highlightll Pharmaceutical
NCT05772520 · Phase 2 · completed
The study was randomized, triple-blind, and placebo-controlled, but it had small dose-specific groups, including 14 participants in the placebo arm. PASI-75 is a clinical endpoint; although the reported response counts favored the 20-mg and 40-mg doses, statistical significance for the primary comparison was not reported.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: brepocitinib's landscape · TLL-018's landscape